Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

8.040 -1.420 (-15.01%)
Streaming Delayed Price Updated: 9:47 AM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024
XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Via ACCESSWIRE
Xenetic Biosciences: Q3 Earnings Insights
 
Via Benzinga
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Via ACCESSWIRE
Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences
 
Via Benzinga
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Via ACCESSWIRE
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Via ACCESSWIRE
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Via ACCESSWIRE
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback